126 related articles for article (PubMed ID: 10914743)
21. Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model.
Ciomei M; Croci V; Ciavolella A; Ballinari D; Pesenti E
Clin Cancer Res; 2006 May; 12(9):2856-61. PubMed ID: 16675581
[TBL] [Abstract][Full Text] [Related]
22. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents.
Knecht R; Peters S; Adunka O; Strebhardt K; Gstoettner W; Hambek M
Anticancer Res; 2003; 23(3B):2577-83. PubMed ID: 12894544
[TBL] [Abstract][Full Text] [Related]
23. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
[TBL] [Abstract][Full Text] [Related]
24. Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts.
Taetle R; Rosen F; Abramson I; Venditti J; Howell S
Cancer Treat Rep; 1987 Mar; 71(3):297-304. PubMed ID: 3815395
[TBL] [Abstract][Full Text] [Related]
25. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
[TBL] [Abstract][Full Text] [Related]
26. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
Weber KL; Doucet M; Price JE; Baker C; Kim SJ; Fidler IJ
Cancer Res; 2003 Jun; 63(11):2940-7. PubMed ID: 12782601
[TBL] [Abstract][Full Text] [Related]
27. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.
Adjei AA; Budihardjo II; Rowinsky EK; Kottke TJ; Svingen PA; Buckwalter CA; Grochow LB; Donehower RC; Kaufmann SH
Clin Cancer Res; 1997 May; 3(5):761-70. PubMed ID: 9815747
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.
Vlassenko AG; Thiessen B; Beattie BJ; Malkin MG; Blasberg RG
J Neurooncol; 2000; 46(3):249-59. PubMed ID: 10902856
[TBL] [Abstract][Full Text] [Related]
29. [Augmented antitumor activity in combination chemotherapy of nedaplatin with etoposide].
Uchida N; Kasai H; Takeda Y; Maekawa R; Sugita K; Yoshioka T
Gan To Kagaku Ryoho; 1998 Jan; 25(1):79-87. PubMed ID: 9464333
[TBL] [Abstract][Full Text] [Related]
30. The hollow fiber assay: continued characterization with novel approaches.
Hall LA; Krauthauser CM; Wexler RS; Hollingshead MG; Slee AM; Kerr JS
Anticancer Res; 2000; 20(2A):903-11. PubMed ID: 10810375
[TBL] [Abstract][Full Text] [Related]
31. Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts.
Dolan ME; Fleig MJ; Feuerstein BG; Basu HS; Luk GD; Casero RA; Marton LJ
Cancer Res; 1994 Sep; 54(17):4698-702. PubMed ID: 8062267
[TBL] [Abstract][Full Text] [Related]
32. Synergy of the combination of nedaplatin with etoposide in murine and human lung carcinoma.
Uchida N; Kasai H; Takeda Y; Maekawa R; Sugita K; Yoshioka T
Anticancer Res; 1998; 18(1A):247-52. PubMed ID: 9568085
[TBL] [Abstract][Full Text] [Related]
33. Increased cytotoxicity of squamous cell carcinoma of the head and neck by combining cisplatin with VP-16 and ciprofloxacin.
Haller J; Burgess R; Dawson D
Laryngoscope; 1993 Oct; 103(10):1081-3. PubMed ID: 8412441
[TBL] [Abstract][Full Text] [Related]
34. In vitro chemosensitivity testing of human tumours by collagen gel droplet culture and image analysis.
Tanigawa N; Kitaoka A; Yamakawa M; Tanisaka K; Kobayashi H
Anticancer Res; 1996; 16(4A):1925-30. PubMed ID: 8712722
[TBL] [Abstract][Full Text] [Related]
35. Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model.
Keane TE; Gingrich JR; Rosner G; Webb KS; Poulton SH; Walther PJ
Cancer Res; 1994 Jan; 54(2):475-81. PubMed ID: 8275484
[TBL] [Abstract][Full Text] [Related]
36. Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine, and mithramycin.
Schold SC; Bigner DD
Cancer Treat Rep; 1983 Sep; 67(9):811-9. PubMed ID: 6224556
[TBL] [Abstract][Full Text] [Related]
37. Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents.
Kelner MJ; McMorris TC; Estes L; Starr R; Samson K; Varki N; Taetle R
Anticancer Res; 1995; 15(3):867-71. PubMed ID: 7645973
[TBL] [Abstract][Full Text] [Related]
38. Novel bifunctional anthracycline and nitrosourea chemotherapy for human bladder cancer: analysis in a preclinical survival model.
Glaves D; Murray MK; Raghavan D
Clin Cancer Res; 1996 Aug; 2(8):1315-9. PubMed ID: 9816302
[TBL] [Abstract][Full Text] [Related]
39. Antitumor efficacy of N1,N11-diethylnorspermine on a human bladder tumor xenograft in nude athymic mice.
Sharma A; Glaves D; Porter CW; Raghavan D; Bernacki RJ
Clin Cancer Res; 1997 Aug; 3(8):1239-44. PubMed ID: 9815805
[TBL] [Abstract][Full Text] [Related]
40. In vivo/ex vivo and in situ assays used in cancer research: a brief review.
Teicher BA
Toxicol Pathol; 2009 Jan; 37(1):114-22. PubMed ID: 19098118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
